Delcath Systems Introduces Healthcare Setting Locator for Hepzato Kit

February 22, 2024—Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced the launch of a Healthcare Setting Locator on the hepzatokit.com website.

Delcath’s Hepzato Kit is a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting < 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. It comprises the chemotherapeutic drug melphalan and Delcath’s Hepatic Delivery System.

Potential patients, caregivers, and healthcare providers can use the Locator to identify healthcare settings, offering treatment with Hepzato Kit.

According to the company, sites included on the Locator are accepting inquiries from patients or their physicians seeking potential treatment with Hepzato Kit. These sites either have or expect to have completed all training and internal approvals necessary to treat a patient subsequent to the normal screening for eligibility.

Melody Burchett, President of A Cure In Sight, an advocacy group for patients with uveal melanoma, commented in the Delcath press release, “The Healthcare Settings Locator is a great resource for mUM patients. Finding treatments is one of the hardest tasks for a mUM patient. With this Locator, patients can find and coordinate care on their own rather than relying only on the treatments their local physician provides.”

Kevin Muir, Delcath’s General Manager of US Interventional Oncology, added, “The Healthcare Setting Locator, which the company will update periodically, is an important tool to assist patients, their caregivers, and their healthcare providers, as they consider appropriate treatment options. The previously announced establishment of the permanent J-Code for Hepzato (J9248) and the launch of the Locator are two important steps in providing information and access to patients for this treatment.”

In the United States, Hepzato Kit is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA, advised the Delcath press release.